Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Aug 21:5:179.
doi: 10.3389/fped.2017.00179. eCollection 2017.

The Centenary of Immune Thrombocytopenia-Part 2: Revising Diagnostic and Therapeutic Approach

Rita Consolini  1 , Giorgio Costagliola  1 , Davide Spatafora  2
Affiliations
Review

The Centenary of Immune Thrombocytopenia-Part 2: Revising Diagnostic and Therapeutic Approach

Rita Consolini et al. Front Pediatr. .

Abstract

Primary immune thrombocytopenia (ITP) is the most common cause of thrombocytopenia in children and adolescents and can be considered as a paradigmatic model of autoimmune disease. This second part of our review describes the clinical presentation of ITP, the diagnostic approach and overviews the current therapeutic strategies. Interestingly, it suggests an algorithm useful for differential diagnosis, a crucial process to exclude secondary forms of immune thrombocytopenia (IT) and non-immune thrombocytopenia (non-IT), which require a different therapeutic management. Advances in understanding the pathogenesis led to new therapeutic targets, as thrombopoietin receptor agonists, whose role in treatment of ITP will be discussed in this work.

Keywords: chronic thrombocytopenia; conventional therapy; diagnostic algorithm; differential diagnosis; immune thrombocytopenia; new therapeutic targets.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Algorithm for differential diagnosis of immune thrombocytopenia, composed by four progressive steps. *Testing for Epstein–Barr virus (EBV), cytomegalovirus (CMV), and HCV is recommended if not done in previous step. **Helycobacter pylori testing should be performed in high prevalence area or clinical suspect.
Figure 2
Figure 2
(Left) The new therapeutic targets identified by the study of pathogenesis of immune thrombocytopenia. (Right) Corresponding drug classes.
See this image and copyright information in PMC

References

    1. Ruggeri M, Fortuna S, Rodeghiero F. Heterogeneity of terminology and clinical definitions in adult idiopathic thrombocytopenic purpura: a critical appraisal from a systematic review of the literature. Haematologica (2008) 93(1):98–103. 10.3324/haematol.11582 - DOI - PubMed
    1. Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood (2009) 113(11):2386–93. 10.1182/blood-2008-07-162503 - DOI - PubMed
    1. Schoonen WM, Kucera G, Coalson J, Li L, Rutstein M, Mowat F, et al. Epidemiology of immune thrombocytopenic purpura in the general practice research database. Br J Haematol (2009) 145(2):235–44. 10.1111/j.1365-2141.2009.07615.x - DOI - PubMed
    1. Segal JB, Powe NR. Prevalence of immune thrombocytopenia: analyses of administrative data. J Thromb Haemost (2006) 4(11):2377–83. 10.1111/j.1538-7836.2006.02147.x - DOI - PubMed
    1. Deane S, Teuber SS, Gershwin ME. The geoepidemiology of immune thrombocytopenic purpura. Autoimmun Rev (2010) 9(5):A342–9. 10.1016/j.autrev.2009.11.020 - DOI - PubMed

LinkOut - more resources